ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Mallinckrodt plans to spin off its specialty generics and active pharmaceutical ingredient (API) business to shareholders, creating two independent companies: Sonorant Therapeutics, focused on branded pharmaceuticals, and Mallinckrodt, focused on generics and APIs. Sonorant will retain the constipation drug Amitiza, which was originally to go with specialty generics. Mallinckrodt said in December that it was considering separating the generics business.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter